An Open-Label Safety, Tolerability, and Efficacy Study in Male and Female Subjects With Androgenetic Alopecia Treated With ATI-50002 Topical Solution

Trial Profile

An Open-Label Safety, Tolerability, and Efficacy Study in Male and Female Subjects With Androgenetic Alopecia Treated With ATI-50002 Topical Solution

Recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Apr 2018

At a glance

  • Drugs ATI 502 (Primary)
  • Indications Alopecia
  • Focus Therapeutic Use
  • Sponsors Aclaris Therapeutics
  • Most Recent Events

    • 23 Apr 2018 According to Aclaris Therapeutics media release, first patient has been dosed.
    • 15 Mar 2018 New trial record
    • 12 Mar 2018 According to Aclaris Therapeutics, trial is expected to begin in the first half of this year data are expected in first half of 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top